Trial Profile

A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects With Systemic Lupus Erythematosus

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Deucravacitinib (Primary)
Indications Systemic lupus erythematosus
Focus Adverse reactions
Acronyms PAISLEY long-term extension (LTE)
Sponsors Bristol-Myers Squibb

Most Recent Events

27 Oct 2025 Results published in the Media Release
25 Oct 2025 According to a Bristol Myers Squibb media release, result data from this study is being presented at the American College of Rheumatology (ACR) Convergence 2025 in Chicago, Illinois taking place from October 24-29, 2025..
17 Apr 2025 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com